Study of Selinexor Plus Bispecific Antibody for Resistant Myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests the drug selinexor in combination with a bispecific antibody for multiple myeloma that has already been treated with at least 4 prior therapies. The goal is to see if the combination is safe and effective for patients whose disease has returned or hasn’t responded to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have multiple myeloma that has come back or hasn't responded after at least 4 different treatments.
- Your previous treatments must have included a proteasome inhibitor (like bortezomib or carfilzomib), an immunomodulatory drug (like lenalidomide or pomalidomide), and a CD38 antibody (like daratumumab).
- You are receiving or will receive a bispecific antibody like teclistamab, elranatamab, or talquetamab as part of approved care.
- Your blood counts, kidney function, and liver function meet certain minimums on recent lab tests.
- You have not already tried selinexor and found it didn’t work.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a three-drug combination (selinexor, ruxolitinib, and methylprednisolone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new combination can help control the cancer.
This Phase 2 trial tests selinexor (a targeted anti-cancer medicine) plus low-dose dexamethasone to treat multiple myeloma that has not responded to many prior treatments. It compares selinexor combinations depending on what medicines you’ve already had, aiming to reduce myeloma activity and improve outcomes.
This trial tests a new drug called SENL103 for people with multiple myeloma that has come back or not responded to several prior treatments. The drug aims to target and kill myeloma cells, potentially helping those who have few other options.
This trial tests a new drug called selinexor (KPT-330) combined with various standard treatments for patients whose multiple myeloma has come back or stopped responding to therapy. The goal is to see if adding selinexor helps control the cancer better than current options, and to find the safest dose for different drug pairings.
This trial tests a combination of four drugs (selinexor, carfilzomib, isatuximab, and dexamethasone) in patients whose multiple myeloma has come back or stopped responding to prior treatment. The goal is to see if this combination can shrink the cancer and help patients whose disease has high-risk features, like certain chromosome changes.
This study tests a new combination of drugs for people with multiple myeloma that has stopped responding to previous treatments. The goal is to see if adding selinexor to other anti-myeloma drugs can help control the disease.
Hear when a new Multiple Myeloma in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.